Effect of Weight‐Neutral Treatment With Semaglutide or Tirzepatide on β‐Cell Identity in db / db Mice
Acta Physiologica · 2026
DOI: 10.1111/apha.70141 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Physiologica, 2026. Verfasst von Zhaobin Deng und 6 weiteren Autor:innen. Beteiligte Einrichtung: Naomi Berrie Diabetes Center and Department of Medicine, Vagelos College of Physicians & Surgeons of Columbia University, New York, New York, USA. Hauptthemen laut MEDLINE: Insulin-Secreting Cells, Glucagon-Like Peptides, Diabetes Mellitus, Type 2, Hypoglycemic Agents. Die Arbeit nennt 49 Literaturangaben. Gefördert von: NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Aim
Insulin resistance and pancreatic β‐cell failure are key characteristics of type 2 diabetes (T2D). Impaired β‐cell function is associated with loss of β‐cell identity, resulting in β‐cell dedifferentiation or trans‐differentiation to other endocrine cells. We have shown that β‐cell dedifferentiation can be reversed, restoring insulin secretion. The aim of this study was to investigate whether semaglutide or tirzepatide treatment can reverse early stages of β‐cell dedifferentiation in db/db mice independent of their effect on body weight.
Methods
After 4 weeks of treatment, 12‐week‐old db/db mice were assessed by oral glucose tolerance test and immunofluorescence to evaluate glucose clearance capacity and effects on pancreatic β‐cell. Body weight, fasting blood glucose, and plasma insulin levels were monitored weekly. Bulk RNA sequencing from islets was performed to identify potential targets.
Results
At the doses employed, tirzepatide stabilized, whereas semaglutide was unable to reverse the weight gain of db/db mice. After a 4‐week course, both groups showed comparable glucose lowering and increased insulin levels. However, both treatments failed to reverse pancreatic β‐cell dedifferentiation, as assessed by either the percentage of cells expressing the dedifferentiation marker ALDH1A3 + or FOXO1 translocation. Furthermore, the number of β‐cells expressing low levels of PDX1 was higher in both treatment groups than in controls. Gene expression analyses showed a muted transcriptional response in overlapping patterns in islets treated with either compound but no obvious candidate target genes.
Conclusion
The findings highlight that the early glucose‐lowering effects of semaglutide and tirzepatide in db/db mice occur independently of changes to β‐cell identity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Naomi Berrie Diabetes Center and Department of Medicine, Vagelos College of Physicians & Surgeons of Columbia University, New York, New York, USA.
- Department of Human Genetics, Leiden University Medical Center, Leiden, the Netherlands.
- School of Biomedical Engineering, Guangzhou Medical University, Guangzhou, People's Republic of China.
ORCID-Profile: Zhaobin Deng
Förderung
- NIH HHS
- National Institutes of Health
Zitieren
APA
Deng, Z., Zheng, D., Son, J., Du, W., McKimpson, W. M., Liu, Q., & Accili, D. (2026). Effect of Weight‐Neutral Treatment With Semaglutide or Tirzepatide on β‐Cell Identity in db / db Mice. Acta Physiologica. https://doi.org/10.1111/apha.70141
Vancouver
Deng Z, Zheng D, Son J, Du W, McKimpson WM, Liu Q, et al. Effect of Weight‐Neutral Treatment With Semaglutide or Tirzepatide on β‐Cell Identity in db / db Mice. Acta Physiologica. 2026. doi:10.1111/apha.70141
BibTeX
@article{Deng2026,
author = {Deng, Zhaobin and Zheng, Dongxu and Son, Jinsook and Du, Wen and McKimpson, Wendy M and Liu, Qingli and Accili, Domenico},
title = {Effect of Weight‐Neutral Treatment With Semaglutide or Tirzepatide on β‐Cell Identity in db / db Mice},
journal = {Acta Physiologica},
year = {2026},
doi = {10.1111/apha.70141}
}
EUVIMED